从技术输出到新基建,一家创新药企的进击之路

药渡
Sep 02

氨基观察-创新药组原创出品作者 | 武月和铂医药最新的半年报远超预期。上半年,公司营收达7.25 亿元,同比大幅增长327%;盈利约5.23亿元,这一数字较去年同期,更是增长51倍,再次创历史新高。这一业绩爆点源于上半年公司持续的BD交易,先后与Windward Bio AG、阿斯利康、大冢制药等达成合作,首付款超2.6亿美元,潜在里程碑款超60亿美元。这再次充分验证了,其将创新能力转化为商业价值...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10